ACE2 News and Research

RSS

Potent pan-β-CoV human monoclonal antibody has in vivo activity in multiple animal models

Researchers evaluated the efficacy of viral spike domain 2-specific human monoclonal antibodies delivered intranasally, against all beta coronaviruses in hamsters and mice.

11 Mar 2022

Study shows SARS-CoV-2 infection induces global alterations of the host endomembrane system

Researchers observed that Golgi fragmentation induced by SARS-CoV-2 facilitates viral trafficking.

11 Mar 2022

Tannic acid plays a role in inhibiting three key molecular pathways involved in SARS-CoV-2 infection

Professor Charles Ramassamy and his postdoctoral researcher Mohamed Haddad at Institut national de la recherche scientifique, in collaboration with scientists from Université de Montréal, McGill University, and Université du Québec à Montréal, believe that tannic acid plays a role in inhibiting three important molecular pathways involved in the SARS-CoV-2 infection.

10 Mar 2022

Natural SARS-CoV-2 infection-induced anti-spike antibody responses

Researchers demonstrated the anti-spike antibody response to SARS-CoV-2 infection and further estimated the acute SARS-CoV-2 infection-induced Ab activity against recently emerged variants like Omicron.

10 Mar 2022

Cross-species infectivity of SARS-CoV-2 variants correlated with prevalence

New research discusses the role of mutations in the receptor-binding domain of the spike protein in the generation of antibody resistance and loss of vaccine efficacy.

10 Mar 2022

Study finds chimeric mRNA induces potent and broadly acting neutralizing antibodies against SARS-CoV-2 variants

Researchers explored strategies to develop an mRNA-based COVID-19 vaccine that could elicit safer and wider protection against SARS-CoV-2 variants of concern.

10 Mar 2022

Engineered SARS-CoV-2 immunogens elicit broadly neutralizing antibodies

New research describes a novel approach whereby SARS-2 antigens were analyzed for conserved sites that may be targeted by broadly neutralizing antibodies that will confer immunity to other Sarbecoviruses.

10 Mar 2022

Study isolated largest panel of β-CoV broadly neutralizing antibodies to date

Researchers isolated a large panel of broadly neutralizing antibodies from COVID-19 recovered-vaccinated donors.

10 Mar 2022

Cedars-Sinai scientists identify potential new therapy for COVID-19

Investigators at Cedars-Sinai have identified a potential new therapy for COVID-19: a biologic substance created by reengineered human skin cells.

9 Mar 2022

Study reveals differential blood glycoprotein profiles in symptomatic and asymptomatic COVID-19 patients

A new study used glycoprotein profiling technology platform that couples high-resolution LC-MS for glycoprotein analysis in regards to COVID-19.

9 Mar 2022

CRIPSR identifies cell-type-specific ACE2 modifiers

Researchers compile a list of candidate genes to identify the surface abundance of functional regulators of ACE2.

9 Mar 2022

Low SARS-CoV-2 diabetogenicity found in infected human pancreatic cells in vitro

Researchers assessed the diabetogenic potential of SARS-CoV-2 in a single cell in vitro analysis on the pancreatic islet cells.

9 Mar 2022

How will mutations change the SARS-CoV-2 spike protein in the future?

A new Cells review discusses the factors that affect the function of the SARS-CoV-2 S protein and provides theoretical limits of this viral protein.

8 Mar 2022

A promising approach for COVID-19 prophylaxis

SARS-CoV-2 viruses can hide from recognition by the immune system. However, the antiviral immune receptor RIG-I can be stimulated, which improves protection against lethal SARS-CoV-2 infections.

8 Mar 2022

SARS-CoV-2 spike protein characteristics responsible for viral evolution in human hosts

Researchers directly compared the pre-fusion spikes of SARS-CoV-2 Alpha and Beta variants with the original Wuhan strain and the D614G-only variant.

8 Mar 2022

Omicron-based vaccine candidate generated to assess whether immunogenicity could be further improved

Researchers developed a vaccine candidate termed Ad26.COV2.S.529, encoding a stabilized Omicron-based S protein resembling ancestral SARS-CoV-2 Wuhan-Hu-1 S protein.

8 Mar 2022

Identification of a rapid test for SARS-CoV-2 neutralization via antibodies and nanobodies

Researchers presented a technique called rapid in vitro inhibition assay (RIVIA), whereby potential SARS-CoV-2 antibody and nanobody candidates can be rapidly screened.

8 Mar 2022

How have human organoids been used in research to study SARS-CoV-2?

In a recent review published in the journal Organoids, scientists have presented an overview on the use of human stem cell-derived organoids in understanding functionality and cellular tropism of severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2), a deadly beta-coronavirus responsible for the ongoing coronavirus disease 2019 (COVID-19) pandemic.

7 Mar 2022

Impact of humoral responses in COVID-19

New research discussed the function and impact of humoral immune responses in COVID-19.

7 Mar 2022

How does COVID-19 affect patients with idiopathic pulmonary fibrosis?

A new study discusses the outcomes of idiopathic pulmonary fibrosis patients with confirmed SARS-CoV-2 infection.

6 Mar 2022

ACE2 News and Research

Potent pan-β-CoV human monoclonal antibody has in vivo activity in multiple animal models

Study shows SARS-CoV-2 infection induces global alterations of the host endomembrane system

Tannic acid plays a role in inhibiting three key molecular pathways involved in SARS-CoV-2 infection

Natural SARS-CoV-2 infection-induced anti-spike antibody responses

Cross-species infectivity of SARS-CoV-2 variants correlated with prevalence

Study finds chimeric mRNA induces potent and broadly acting neutralizing antibodies against SARS-CoV-2 variants

Engineered SARS-CoV-2 immunogens elicit broadly neutralizing antibodies

Study isolated largest panel of β-CoV broadly neutralizing antibodies to date

Cedars-Sinai scientists identify potential new therapy for COVID-19

Study reveals differential blood glycoprotein profiles in symptomatic and asymptomatic COVID-19 patients

CRIPSR identifies cell-type-specific ACE2 modifiers

Low SARS-CoV-2 diabetogenicity found in infected human pancreatic cells in vitro

How will mutations change the SARS-CoV-2 spike protein in the future?

A promising approach for COVID-19 prophylaxis

SARS-CoV-2 spike protein characteristics responsible for viral evolution in human hosts

Omicron-based vaccine candidate generated to assess whether immunogenicity could be further improved

Identification of a rapid test for SARS-CoV-2 neutralization via antibodies and nanobodies

How have human organoids been used in research to study SARS-CoV-2?

Impact of humoral responses in COVID-19

How does COVID-19 affect patients with idiopathic pulmonary fibrosis?

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News